JP2024540199A5 - - Google Patents
Info
- Publication number
- JP2024540199A5 JP2024540199A5 JP2024525780A JP2024525780A JP2024540199A5 JP 2024540199 A5 JP2024540199 A5 JP 2024540199A5 JP 2024525780 A JP2024525780 A JP 2024525780A JP 2024525780 A JP2024525780 A JP 2024525780A JP 2024540199 A5 JP2024540199 A5 JP 2024540199A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- light chain
- seq
- heavy chain
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163274306P | 2021-11-01 | 2021-11-01 | |
| US63/274,306 | 2021-11-01 | ||
| PCT/US2022/078975 WO2023077120A1 (en) | 2021-11-01 | 2022-10-31 | Muscle targeting complexes for treating dystrophinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540199A JP2024540199A (ja) | 2024-10-31 |
| JP2024540199A5 true JP2024540199A5 (cg-RX-API-DMAC7.html) | 2026-01-19 |
Family
ID=86158573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525780A Pending JP2024540199A (ja) | 2021-11-01 | 2022-10-31 | ジストロフィノパチーを処置するための筋標的化複合体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20260137797A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4426356A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024540199A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240095330A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118201640A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022377070A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3233308A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312142A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005332A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023077120A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG186451A1 (en) * | 2010-07-12 | 2013-01-30 | Covx Technologies Ireland Ltd | Multifunctional antibody conjugates |
| US20130323234A1 (en) * | 2012-01-09 | 2013-12-05 | Covx Technologies Ireland Limited | Mutant antibodies and conjugation thereof |
| US10758607B2 (en) * | 2015-06-17 | 2020-09-01 | The Research Institute At Nationwide Children's Hospital | Respiratory syncytial virus having cleavage-resistant G protein and related materials and methods |
| TWI737736B (zh) * | 2016-05-24 | 2021-09-01 | 美商薩羅塔治療公司 | 製備磷醯二胺嗎啉代寡聚物之方法 |
| US20200155702A1 (en) * | 2017-06-16 | 2020-05-21 | Eli Lilly And Company | Engineered Antibody Compounds and Conjuates Thereof |
| CN122124274A (zh) * | 2020-01-10 | 2026-06-02 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途 |
-
2022
- 2022-10-31 EP EP22888561.2A patent/EP4426356A1/en active Pending
- 2022-10-31 KR KR1020247018073A patent/KR20240095330A/ko active Pending
- 2022-10-31 CA CA3233308A patent/CA3233308A1/en active Pending
- 2022-10-31 JP JP2024525780A patent/JP2024540199A/ja active Pending
- 2022-10-31 MX MX2024005332A patent/MX2024005332A/es unknown
- 2022-10-31 AU AU2022377070A patent/AU2022377070A1/en active Pending
- 2022-10-31 US US18/706,057 patent/US20260137797A1/en active Pending
- 2022-10-31 WO PCT/US2022/078975 patent/WO2023077120A1/en not_active Ceased
- 2022-10-31 CN CN202280073596.0A patent/CN118201640A/zh active Pending
- 2022-10-31 IL IL312142A patent/IL312142A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL320340A (en) | Muscle targeting complexes and uses thereof for skipping exon 45 of a dmd gene | |
| JP2023510350A5 (cg-RX-API-DMAC7.html) | ||
| IL312142A (en) | Muscle targeting complexes for the treatment of dystrophinopathy | |
| JP2025512469A5 (cg-RX-API-DMAC7.html) | ||
| IL309936A (en) | Muscle targeting complexes and formulations for treating dystrophinopathies | |
| JP2024527362A5 (cg-RX-API-DMAC7.html) | ||
| JP2024525610A5 (cg-RX-API-DMAC7.html) | ||
| JP2024534488A5 (cg-RX-API-DMAC7.html) | ||
| JP2024525611A5 (cg-RX-API-DMAC7.html) | ||
| IL311507A (en) | Dosing of muscle targeting complexes for the treatment of dystrophinopathy | |
| JP2024525613A5 (cg-RX-API-DMAC7.html) | ||
| JP2023535073A5 (cg-RX-API-DMAC7.html) | ||
| JP2024525612A5 (cg-RX-API-DMAC7.html) | ||
| JP7041516B2 (ja) | 共通軽鎖を有する二重特異性抗体又は抗体混合物 | |
| IL315944A (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| TWI769537B (zh) | 標靶bcma的抗體、雙專一性抗體及其用途 | |
| JP2023509793A5 (cg-RX-API-DMAC7.html) | ||
| JP2021532831A5 (cg-RX-API-DMAC7.html) | ||
| IL316143A (en) | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy | |
| JP2025512468A5 (cg-RX-API-DMAC7.html) | ||
| JP2024524222A5 (cg-RX-API-DMAC7.html) | ||
| JP7663977B2 (ja) | 抗pd―l1抗体およびその用途 | |
| IL309912A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| JP2012504401A5 (cg-RX-API-DMAC7.html) |